The iShares Nasdaq Biotechnology ETF (IBB) is currently down more than 21% since the stock markets opened on January 4, hovering around $258, after dipping as low as $244 two weeks ago. But back in July, shares in the ETF were priced around $400.
Avalanche Biotechnologies. The gene therapy company debuted in the $20s in 2014 before shooting up to $60 in January last year. However, Avalanche came crashing down and lost 50% of its value in one day's pre-market trading alone back in June due to concern over clinical trial results. Currently, it's priced around $5
The analysts recommend Regeneron and Celgene as the top two picks for waiting out the recovery.
The Street
25 Canada Square, Level 33, office 50, Canary Wharf London, E14 5LQ +44 20 3608 6256
World Financial Markets - 0700 17 600 Varchev Exchange - 0700 115 44
Varchev Finance Ltd is registered in the FCA (FINANCIAL CONDUCT AUTHORITY) with a passport in the United Kingdom: FCA, United Kingdom - registration number: 494 045, which allows provision of financial services in the United Kingdom.
Varchev Finance Ltd strictly comply with the statutes of the European directive MiFID (Markets in Financial Instruments). targeting increased efficiency, transparency and uniformity of financial instruments.
Varchev Finance Ltd is authorized and regulated by the Financial Supervision Commission - Sofia, Bulgaria: License number RG-03-02-05 / 15.03.2006
The information on this site is not intended for distribution or use by any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.
Disclaimer:
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 63,41% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.